You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Targeting DNA Damage Response

As research advances, we continue to expand our knowledge and understanding of novel targets in DNA damage response as potential therapeutic options in oncology. While PARP inhibitors have led the way, and are increasingly being recognized as a targeted therapeutic approach for patients with BRCA mutations and other indicators of susceptibility, agents targeting different DNA damage response pathways may potentially reshape the treatment landscape in oncology in the near future.

This curriculum explores the recent clinical advances with agents targeting different aspects of DNA damage response, their rationale for use, and emerging clinical data.

Supported by an independent educational grant from

AstraZeneca Pharmaceuticals LP

CME Activities

Polling Question

You must log in to answer this question
How confident are you in managing grade 2 nausea in a patient with advanced ovarian cancer receiving PARP inhibitor therapy?
Very confident
Somewhat confident
Neither confident nor unsure
Somewhat unsure
Very unsure

Related Resources

Steering Committee

Don S. Dizon, MD

Steering Committee Chair

Clinical Co-Director, Gynecologic Oncology; Director, The Oncology Sexual Health Clinic, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Robert L. Coleman, MD

Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas

Mark E. Robson, MD

Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York

Elizabeth Swisher, MD

Professor, Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington

Richard T. Penson, MD, MRCP

Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital, Boston, Massachusetts

Kimberly L. Blackwell, MD

Professor of Medicine, Duke University Medical Center, Durham, North Carolina